|
1
|
Steuer CE, Behera M, Liu Y, Fu C,
Gillespie TW, Saba NF, Shin DM, Pillai RN, Pakkala S, Owonikoko TK,
et al: Pulmonary sarcomatoid carcinoma: An analysis of the national
cancer data base. Clin Lung Cancer. 18:286–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chang YL, Lee YC, Shih JY and Wu CT:
Pulmonary pleomorphic (spindle) cell carcinoma: Peculiar
clinicopathologic manifestations different from ordinary non-small
cell carcinoma. Lung Cancer. 34:91–97. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: Impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tamura Y, Fujiwara Y, Yamamoto N, Nokihara
H, Horinouchi H, Kanda S, Goto Y, Kubo E, Kitahara S, Tsuruoka K,
et al: Retrospective analysis of the efficacy of chemotherapy and
molecular targeted therapy for advanced pulmonary pleomorphic
carcinoma. BMC Res Notes. 8:8002015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rossi G, Cavazza A, Sturm N, Migaldi M,
Facciolongo N, Longo L, Maiorana A and Brambilla E: Pulmonary
carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements:
A clinicopathologic and immunohistochemical study of 75 cases. Am J
Surg Pathol. 27:311–324. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuki T, Sakuma T, Ohbayashi C, Yoshimura
M, Tsubota N, Okita Y and Okada M: Pleomorphic carcinoma of the
lung: A surgical outcome. J Thorac Cardiovasc Surg. 134:399–404.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Awad MM, Oxnard GR, Jackman DM, Savukoski
DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S,
et al: MET Exon 14 mutations in non-small-cell lung cancer are
associated with advanced age and stage-dependent MET genomic
amplification and c-Met overexpression. J Clin Oncol. 34:721–730.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fishback NF, Travis WD, Moran CA, Guinee
DG Jr, McCarthy WF and Koss MN: Pleomorphic (spindle/giant cell)
carcinoma of the lung. A clinicopathologic correlation of 78 cases.
Cancer. 73:2936–2945. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frampton GM, Ali SM, Rosenzweig M,
Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D,
et al: Activation of MET via diverse exon 14 splicing alterations
occurs in multiple tumor types and confers clinical sensitivity to
MET inhibitors. Cancer Discov. 5:850–859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tong JH, Yeung SF, Chan AWH, Chung LY,
Chau SL, Lung RWM, Tong CY, Chow C, Tin EKY, Yu YH, et al: MET
amplification and exon 14 splice site mutation define unique
molecular subgroups of non-small cell lung carcinoma with poor
prognosis. Clin Cancer Res. 22:3048–3056. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riely GJ, Wood DE, Aisner DL, Loo BW Jr,
Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, et
al: NCCN guidelines® insights: Non-small cell lung
cancer, version 7.2025. J Natl Compr Canc Netw. 23:354–362. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reuss JE, Kuruvilla S, Ismaila N, Azar IH,
Feldman J, Furuya N, Wheatley-Price P, Roof L, Velazquez AI, Wang Y
and Leighl NB: Therapy for stage IV non-small cell lung cancer with
driver alterations: ASCO living guideline, version 2025.1. J Clin
Oncol. 43:e31–e44. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hendriks LEL, Cortiula F, Martins-Branco
D, Mariamidze E, Popat S and Reck M; ESMO Guidelines Committee.
Electronic address, : simpleclinicalguidelines@esmo.org:
Updated treatment recommendations for systemic treatment: From the
ESMO oncogene-addicted metastatic NSCLC living guideline. Ann
Oncol. 36:1227–1231. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paik PK, Felip E, Veillon R, Sakai H,
Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van
Meerbeeck J, et al: Tepotinib in non-small-cell lung cancer with
MET exon 14 skipping mutations. N Engl J Med. 383:931–943. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wolf J, Seto T, Han JY, Reguart N, Garon
EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, et al:
Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell
lung cancer. N Engl J Med. 383:944–957. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q,
Liang Z, Cheng Y, Jiang L, Yang N, et al: Once-daily savolitinib in
Chinese patients with pulmonary sarcomatoid carcinomas and other
non-small-cell lung cancers harbouring MET exon 14 skipping
alterations: A multicentre, single-arm, open-label, phase 2 study.
Lancet Respir Med. 9:1154–1164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagano M, Kohsaka S, Hayashi T, Ueno T,
Kojima S, Shinozaki-Ushiku A, Morita S, Tsuda M, Tanaka S,
Shinohara T, et al: Comprehensive molecular profiling of pulmonary
pleomorphic carcinoma. NPJ Precis Oncol. 5:572021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujino T, Kobayashi Y, Suda K, Koga T,
Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T and
Mitsudomi T: Sensitivity and resistance of MET exon 14 mutations in
lung cancer to eight MET tyrosine kinase inhibitors in vitro. J
Thorac Oncol. 14:1753–1765. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao Y, Yang H, Zhu B, Wang S, Pang J, Wu
X, Xu Y, Zhang J, Zhang J, Ou Q, et al: Mutations in the MET
tyrosine kinase domain and resistance to tyrosine kinase inhibitors
in non-small-cell lung cancer. Respir Res. 24:282023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vieira T, Antoine M, Hamard C, Fallet V,
Duruisseaux M, Rabbe N, Rodenas A, Cadranel J and Wislez M:
Sarcomatoid lung carcinomas show high levels of programmed death
ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells
and macrophages. Lung Cancer. 98:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hazama D, Nakahama K, Kodama H, Miyazaki
A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, et
al: Effectiveness and safety of immune checkpoint inhibitors alone
or in combination with chemotherapy in pulmonary sarcomatoid
carcinoma. JTO Clin Res Rep. 5:1006132024.PubMed/NCBI
|
|
22
|
Domblides C, Leroy K, Monnet I, Mazières
J, Barlesi F, Gounant V, Baldacci S, Mennecier B, Toffart AC,
Audigier-Valette C, et al: Efficacy of immune checkpoint inhibitors
in lung sarcomatoid carcinoma. J Thorac Oncol. 15:860–866. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim M, Keam B, Ock CY, Kim SH, Kim YJ, Lim
SM, Kim JS, Kim TM, Hong SH, Ahn MS, et al: Phase II study of
durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma:
KCSG-LU16-07. Thorac Cancer. 11:3482–3489. 2020. View Article : Google Scholar : PubMed/NCBI
|
